GEHC vs ABBV
organic revenue · AbbVie
| GEHC organic revenue Healthcare | ABBV AbbVie Healthcare | |
|---|---|---|
| Market | ||
| Price | $79.51 -0.05% | $290.84 +0.69% |
| Market cap | $34.6B | $521.1B |
| P/E (TTM) | 17.4 | 82.6 |
| Dividend yield | 0.16% | 4.47% |
| 52-week range | $58.75 – $89.77 | $190.75 – $298.74 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | GE HealthCare Expanded Margin 180 Basis Points, With A $55M Tariff Refund Nov 3, 2026 | AbbVie Q3 2026: Skyrizi And Rinvoq Are 49% Of Revenue, And Adjusted EPS Includes IPR&D Nov 2, 2026 |
| Latest earnings | ||
| Reported | — | Oct 30, 2026 |
| Revenue | — | $17.404 billion +10.3% YoY |
| EPS | — | $2.37 |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +10.3% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.